Abstract
The aim of this study was to compare the safety, efficacy, tolerability, and the effects of atomoxetine and OROS-MPH on executive functions in children with ADHD. This study was an open-label study that only included two medication groups. Children were randomized to open-label atomoxetine or OROS-MPH for 12 weeks. Primary efficacy measures were T-DSM-IV-S, CGI-I and neuropsychological tests battery. Safety assessments included electrocardiogram, adverse events checklist and laboratory tests. According to the endpoint improvement scores of CGI and parents T-DSM-IV-S, treatment responses were not significantly different between the two study groups. OROS-MPH led to a significantly greater reduction in teacher T-DSM-IV-S scale scores. OROS-MPH was more effective than atomoxetine on Stroop-5 time and number of corrections. Significant decrease in the percentage of perseverative errors on WCST in the OROS-MPH group was seen (p = 0.005). The most frequently reported adverse events in the atomoxetine group were anorexia, nausea, nervousness, weight loss, abdominal pain, and somnolence. In the OROS-MPH group, patients most frequently reported anorexia, nervousness, insomnia, headache, nausea, and weight loss. When all these results are considered, although both drugs can be considered effective in ADHD treatment, more remarkable improvement is provided by OROS-MPH based on the rates across informant (i.e., teachers, clinicians) and neuropsychological evaluation.
Similar content being viewed by others
References
American Psychiatric Association (APA) (2000) Diagnostic and statistical manual of mental disorders, 4th edition-text revision (DSM-IV-TR). APA, Washington, DC
Biederman J, Spencer TJ (1999) Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 46:1234–1242
Safer DJ (2000) Commentary: stimulant treatment in the community. J Am Acad Child Adolesc Psychiatry 39:989–992
Popper CW (2000) Pharmacological alternatives to psychostimulants for the treatment of attention deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 9:605–646
Connor DF, Fletcher KE, Swanson JM (1999) A meta analysis of clonidine for symptoms of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 38:1551–1560
Higgins ES (1999) A comparative analysis of antidepressants and stimulants for the treatment of adults with attention-deficit hyperactivity disorder. J Fam Pract 48:15–20
Scahill L, Chappell PB, Kim YS, Katsovich L, Sheperd E et al (2001) A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 158:1067–1074
Silver LB (1999) Alternative (nonstimulant) medications in the treatment of attention-deficit/hyperactivity disorder in children. Pediatr Clin North Am 46:965–975
Wilens TE, Biederman J, Baldessarini RJ, Geller B, Schleifer D, Spencer TJ et al (1996) Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry 35:1491–1501
Sauer JM, Ponsler GD, Mattiuz EL, Long AJ, Witcher JW, Thomasson HR et al (2003) Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos 31:98–107
Biederman J, Heiligenstein JH, Faries DE, Galil N, Dittmann R, Emslie GJ et al (2002) Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics 110:e75
Michelson D, Faries DE, Wernicke J et al (2001) Atomoxetine in the treatment of children and adolescents with ADHD: a randomized, placebo-controlled dose-response study. Pediatrics 108:e83
Takahashi M, Takita Y, Yamazaki K et al (2009) A randomized, double-blind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmachol 19:341–350
Kemner JE, Starr HL, Ciccone PE, Hooper-Wood CG, Crockett RS (2005) Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv Ther 22:498–512
Kratochvil CJ, Heiligenstein J, Dittmann R, Spencer TJ, Biederman J, Wernicke J et al (2002) Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 41:776–784
Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ et al (2008) Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 165:721–730
Wigal SB, McGough JJ, McCracken JT, Biederman J, Spencer TJ, Posner KL et al (2005) A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 9:275–289
Barkley RA (1997) Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 121:65–94
Nigg JT (2005) Neuropsychologic theory and findings in attention-deficit/hyperactivity disorder: the state of the field and salient challenges for the coming decade. Biol Psychiatry 57:1424–1435
Shallice T, Marzocchi GM, Coser S, Del Savio M, Meuter RF, Rumiah RI (2002) Executive function profile of children with attention deficit hyperactivity disorder. Dev Neuropsychol 21:43–71
Kaufman J, Birmaher B, Brent D (1997) Schedule for affective disorders and schizophrenia for school age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980–988
Guy E (1976) Assessment manual for psychopharmacology. National Institute of Mental Health, Rockville
Ercan ES, Amado S, Somer O (2001) Development of a test battery for attention deficit hyperactivity and disruptive behavior disorders. Cocuk ve Genclik Ruh Saglıgı Dergisi 8:132–144
Wechsler D (1949) Manual of the wechsler intelligence scale for children. Psychological Corporation, San Antonio
Turgay A (1994) Disruptive behavior disorders child and adolescent screening and rating scales for children, adolescents, parents, and teachers. Integrative Therapy Institute Publication, West Blomfield
Heaton RK (1981) A manual for wisconsin card sorting test. Psychological Assessment Resources, Odessa FL
Karakas S (2004) BILNOT bataryası El kitabı: Nöropsikiyatrik testler icin arastırma ve geli tirme cabaları. Hacettepe Üniversitesi Yayinlari, Ankara
Stroop JR (1935) Studies of interference in serial verbal reactions. J Exp Psychol 18:643–662
Kilic BG, Kockar AY, Irak M, Sener S, Karakas S (2002) Stroop Testi TBAG Formunun 6–11 yas grubu cocuklarda standardizasyon calismasi. Cocuk ve Genclik Ruh Sagligi Dergisi 9(2):86–99
Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C et al (2002) Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, Placebo-controlled study. Am J Psychiatry 159:1896–1901
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yildiz, O., Sismanlar, S.G., Memik, N.C. et al. Atomoxetine and Methylphenidate Treatment in Children with ADHD: The Efficacy, Tolerability and Effects on Executive Functions. Child Psychiatry Hum Dev 42, 257–269 (2011). https://doi.org/10.1007/s10578-010-0212-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10578-010-0212-3